studies

mNSCLC - L1 - PDL1 negative, nivolumab based treatment vs. platinum association, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 0.78 [0.60; 1.02] 0.78[0.60; 1.02]CheckMate 227 (NC vs C ; PDL1<1%), 201810%363NAnot evaluable progression or deaths (PFS)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 0.73 [0.56; 0.95] 0.73[0.56; 0.95]CheckMate 227 (NC vs C ; PDL1<1%), 201810%363NAnot evaluable STRAE (any grade)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.75 [1.00; 3.09] 1.75[1.00; 3.09]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable STRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 2.05 [1.12; 3.76] 2.05[1.12; 3.76]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable TRAE (any grade)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 3.42 [1.76; 6.65] 3.42[1.76; 6.65]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 2.35 [1.53; 3.60] 2.35[1.53; 3.60]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 4.33 [0.48; 39.16] 4.33[0.48; 39.16]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 0.89 [0.48; 1.63] 0.89[0.48; 1.63]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 0.80 [0.38; 1.70] 0.80[0.38; 1.70]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.34 [0.75; 2.38] 1.34[0.75; 2.38]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.07; 17.15] 1.06[0.07; 17.15]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 0.26 [0.01; 5.89] 0.26[0.01; 5.89]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48] 1.43[0.32; 6.48]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.15; 7.64] 1.06[0.15; 7.64]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 2.18 [0.65; 7.39] 2.18[0.65; 7.39]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 0.85 [0.22; 3.21] 0.85[0.22; 3.21]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.19 [0.63; 2.24] 1.19[0.63; 2.24]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.02; 53.93] 1.06[0.02; 53.93]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 2.13 [0.07; 64.04] 2.13[0.07; 64.04]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48] 1.43[0.32; 6.48]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-11-05 21:18 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 174 - treatments: 855,360,719,721,720,842,642,674,1085,863

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons